observational, retrospective study to evaluate coagulation changes and the influence of antithrombin iii treatment in patients with severe covid-19 infection

Conditions: Covid19

Summary: multicentre, multinational, non-interventional, observational, retrospective, patient record study to evaluate changes in coagulation parameters in patients with severe covid-19 infection receiving/not treatment with antithrombin (at) iii


Eligibility criteria:
for sites in austria: inclusion criteria: for the +covid-19 group: * confirmed covid-19 positive test result or extremely high likelihood of covid-19 infection (e.g., family member or other person co-habiting with subject with a documented infection; passenger from cruise ship with +covid- 19) * hospitalisation for severe covid-19 infection until 01.06.2020 * covid-19 patients having required oxygen therapy as per local guidelines (including those requiring a ventilator, central venous catheter or ecmo) for the control group: * hospitalisation for any disease other than covid-19 infection until end 2019 (31.12.2019) * patients having required oxygen therapy as per local guidelines (including those requiring a ventilator, central venous catheter or ecmo) exclusion criteria: * known hypersensitivity or allergic reaction to atiii * participation in any interventional trial during the time of individual observational period (date of hospitalisation to the date of removal of oxygen therapy or death, whichever occurred first) * pregnant women for sites in france: inclusion criteria: for the +covid-19 group: * confirmed covid-19 positive test result or extremely high likelihood of covid-19 infection (e.g., family member or other person co-habiting with subject with a documented infection; passenger from cruise ship with +covid-19) * hospitalisation for severe covid-19 infection and discharged from the hospital or died before start of documentation. covid-19 patients having required oxygen therapy as per local guidelines (including those requiring a ventilator, central venous catheter or ecmo) for the control group: * hospitalisation for any disease other than covid-19 infection until end 2019 (31.12.2019) * patients having required oxygen therapy as per local guidelines (including those requiring a ventilator, central venous catheter or ecmo) exclusion criteria: * known hypersensitivity or allergic reaction to atiii * participation in any interventional trial during the time of individual observational period (date of hospitalisation to the date of removal of oxygen therapy or death, whichever occurred first) * pregnant women for sites in germany: inclusion criteria: for the +covid-19 group: * confirmed covid-19 positive test result or extremely high likelihood of covid-19 infection (e.g., family member or other person co-habiting with subject with a documented infection; passenger from cruise ship with +covid-19) * hospitalisation for severe covid-19 infection until 01.02.2021. * covid-19 patients having required oxygen therapy as per local guidelines (including those requiring a ventilator, central venous catheter or ecmo) for the control group: * hospitalisation for any disease other than covid-19 infection until end 2019 (31.12.2019) * patients having required oxygen therapy as per local guidelines (including those requiring a ventilator, central venous catheter or ecmo) exclusion criteria: * known hypersensitivity or allergic reaction to atiii * participation in any interventional trial during the time of individual observational period (date of hospitalisation to the date of removal of oxygen therapy or death, whichever occurred first) * pregnant women